Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Becton, Dickinson and Company for the period ended June 30, 1996. The company operates in the medical supplies, devices, and diagnostic systems sectors. The report covers the third quarter and the first nine months of fiscal year 1996, comparing results to the same periods in 1995.
Key Financial Metrics
| Metric | Q3 1996 | Q3 1995 | 9 Months 1996 | 9 Months 1995 |
|---|---|---|---|---|
| Revenues | $692.9 million | $704.1 million | $2,038.6 million | $1,990.4 million |
| Net Income | $77.2 million | $66.7 million | $196.5 million | $165.1 million |
| Earnings Per Share | $1.15 | $0.95 | $2.90 | $2.33 |
| Operating Income | $120.0 million | $109.9 million | $304.8 million | $275.7 million |
| Gross Profit Margin | 49.2% | 46.3% | 47.5% | 46.0% |
| Operating Margin | 17.3% | 15.6% | 15.0% | 13.9% |
| Cash from Operations (9mo) | $299.0 million | $339.7 million | ||
| Capital Expenditures (9mo) | ||||
| Short-Term Debt | $427.2 million | $205.8 million (Sep 1995) | ||
| Long-Term Debt | $371.9 million | $557.6 million (Sep 1995) | ||
| Cash and Equivalents | $187.8 million | $198.5 million (Sep 1995) |
Material Changes vs. Prior Period
- Revenue: Q3 reported revenue decreased 1.6% year-over-year. However, management estimates that excluding the impact of divestitures (glove business, contract packaging, surgical product line) and a stronger dollar, organic revenue growth was approximately 6%.
- Profitability: Net income increased 16% in Q3 and 19% for the nine-month period. Gross margins improved significantly (49.2% in Q3 vs. 46.3% prior year) due to a more profitable product mix and productivity gains.
- Debt Structure: Total debt decreased significantly. The company redeemed $66.4 million of 9 1/4% Sinking Fund Debentures in June 1996. Short-term debt increased to fund operations and acquisitions, while long-term debt was reduced.
- Share Repurchases: The company repurchased 3.2 million shares for $244 million during the first nine months of 1996, contributing to the increase in earnings per share.
Guidance, Outlook, and Risks
- Stock Split: On July 23, 1996, the Board authorized a two-for-one common stock split payable on August 15, 1996.
- Capital Expenditures: Full-year capital expenditures are expected to be approximately $150 million, driven by international expansion.
- Share Repurchase Plan: The company expects to spend approximately $300 million on share repurchases for the full year. A new plan to acquire an additional 15 million shares (post-split) was authorized.
- Tax Rate: The effective tax rate for fiscal 1996 is expected to be 28%.
- Risks/Contingencies:
- Currency: A stronger dollar negatively impacted reported revenues by an estimated $17 million in Q3.
- Market Conditions: Domestic Diagnostic revenues are unfavorably impacted by cost containment initiatives in the marketplace.
- Accounting Standards: The company is assessing the impact of FASB Statement No. 121 regarding impairment of long-lived assets, required for adoption in fiscal 1997, though no material impact is currently expected.
Investor Verification Checklist
- Verify the organic revenue growth rate of ~6% by reviewing the specific divestiture amounts and currency translation adjustments detailed in the MD&A.
- Confirm the impact of the $66.4 million debt redemption on future interest expense and liquidity.
- Monitor the execution of the new 15 million share repurchase plan and the timing of the two-for-one stock split.
- Assess the sustainability of the improved gross margins (49.2% in Q3) given the competitive pressure and cost containment in the domestic diagnostic market.
- Review the "Other expense, net" line item for non-recurring gains or losses related to asset sales and real estate adjustments.